21 CFR Part 11 Compliance Guide for Clinical Trial EDC Systems

Introduction

If your clinical trial uses an Electronic Data Capture (EDC) system — or you're planning to adopt one — 21 CFR Part 11 is the most important regulation you need to understand. Published by the U.S. Food and Drug Administration (FDA), 21 CFR Part 11 defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.

Failure to comply means your trial data could be rejected during an FDA inspection. This guide explains everything you need to know about 21 CFR Part 11 compliance for EDC systems, including specific requirements and how QuantClinica meets them.

What is 21 CFR Part 11?

21 CFR Part 11 is a section of the Code of Federal Regulations that establishes the FDA's requirements for electronic records and electronic signatures. It applies to all clinical research involving FDA-regulated products, including drugs, biologics, and medical devices.

The regulation has three main components:

• Electronic Records (Subpart B): Requirements for closed and open systems, including validation, audit trails, and record retention.
• Electronic Signatures (Subpart C): Requirements for signature manifestations, identity verification, and linking signatures to records.
• General Provisions (Subpart A): Scope, definitions, and implementation guidelines.

Why 21 CFR Part 11 Matters for EDC Systems

EDC systems are the backbone of modern clinical trial data management. They capture, store, and transmit critical patient data, laboratory results, and investigator observations. The FDA requires that these systems maintain data integrity throughout the trial lifecycle — from initial data entry through database lock and archiving.

Without Part 11 compliance, you risk:

• FDA Form 483 observations and Warning Letters
• Clinical hold on your trial
• Rejection of New Drug Application (NDA) submissions
• Legal liability and reputational damage

Key 21 CFR Part 11 Requirements for EDC Platforms

1. System Validation (Section 11.10(a))

Your EDC system must be validated to ensure accuracy, reliability, and consistent intended performance. This includes installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).

2. Audit Trails (Section 11.10(e))

EDC systems must generate secure, computer-generated, time-stamped audit trails that independently record who made changes, what was changed, when, and why. The audit trail must be available for review and cannot be deleted or modified.

3. Authority Checks (Section 11.10(g) and (h))

Systems must enforce authority checks to ensure only authorized users can access the system and perform operations within their assigned role. This includes device checks to verify the identity of the terminal or workstation.

4. Electronic Signatures (Section 11.50, 11.70, 11.100, 11.200)

Electronic signatures must include at least two distinct identification components (user ID and password). Each signature must be unique to one individual and cannot be reused or reassigned. Signatures must display the printed name of the signer, date and time, and the meaning of the signature.

5. Record Retention (Section 11.10(c))

Records must be retained for the period specified by applicable FDA regulations and must be readily retrievable throughout the retention period. Electronic copies must be available for inspection by the FDA.

How QuantClinica EDC Ensures 21 CFR Part 11 Compliance

QuantClinica EDC was built from the ground up with 21 CFR Part 11 compliance at its core. Here is how we address each requirement:

• Validation: Comprehensive validation documentation package available, including IQ/OQ/PQ protocols.
• Audit Trails: Immutable, encrypted audit logs capture every data change with user ID, timestamp, previous and new values, and reason for change.
• Electronic Signatures: Two-factor authentication with unique user credentials. Each signature displays full name, date/time, and signing meaning (e.g., "Reviewed," "Approved," "Verified").
• Access Control: Role-based access with granular permissions for Sponsors, CROs, Investigators, Monitors, and Data Managers.
• Record Retention: Secure cloud storage with configurable retention periods and export capabilities in standard formats including CDISC SDTM.

Common 21 CFR Part 11 Compliance Mistakes

1. Using shared login credentials or generic user accounts
2. Failing to validate the system for its intended use
3. Not maintaining an adequate audit trail for review
4. Allowing deletion or modification of audit trail records
5. Using electronic signatures without proper identity verification
6. Not training staff on Part 11 requirements and system use

EDC Compliance Checklist

Use this checklist to evaluate whether your EDC system meets 21 CFR Part 11 requirements:

• System validated with documented IQ/OQ/PQ
• Secure audit trails enabled for all data changes
• Unique user IDs and passwords enforced
• Role-based access control configured
• Electronic signatures display printed name, date/time, meaning
• Records retained per FDA requirements
• Copies of records producible in human-readable format
• Training completed for all system users
• Standard operating procedures (SOPs) in place
• Periodic system review and re-validation scheduled

Conclusion

21 CFR Part 11 compliance is not optional for clinical trial EDC systems — it is a regulatory requirement that directly impacts your ability to submit and gain approval for new drugs and devices. By choosing a compliant EDC platform like QuantClinica and following the practices outlined in this guide, you can ensure your trial data meets the highest standards of integrity and regulatory acceptance.

Ready to see how QuantClinica EDC can support your 21 CFR Part 11 compliance? Contact our team for a personalized demo.

← Back to Blog